- Home
- ALLO
as 05-21-2025 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 371.8M | IPO Year: | 2018 |
| Target Price: | $8.90 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $3.78 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | -76.84% |
| Revenue Growth (this year): | -30.45% | Revenue Growth (next year): | 9.07% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yoshiyama Annie | ALLO | SVP, Finance | Apr 21 '25 | Sell | $1.41 | 9,601 | $13,537.41 | 130,663 | |
| Chang David D | ALLO | President and CEO | Mar 14 '25 | Sell | $1.96 | 46,668 | $91,469.28 | 5,276,569 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Mar 14 '25 | Sell | $1.98 | 5,488 | $10,838.80 | 218,507 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
GuruFocus.com
7 days ago
Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays
Zacks
7 days ago
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Thomson Reuters StreetEvents
8 days ago
Q1 2025 Allogene Therapeutics Inc Earnings Call
MT Newswires
8 days ago
Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating
MT Newswires
8 days ago
Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating
Zacks
8 days ago
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
GuruFocus.com
8 days ago
Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...
Associated Press Finance
8 days ago
Allogene Therapeutics: Q1 Earnings Snapshot
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.